Precision Medicine Delays Chemotherapy for Stage 4 Breast Cancer Patients, Balancing Career and Treatment
NQ Score
81/100
AI Summary (NQ-processed)
A 50-year-old woman with stage 4 hormone receptor-positive breast cancer successfully managed her career and family thanks to early adoption of precision medicine. Dr. Chen Peng-yu noted that precision medicine can extend the stable period for patients with specific gene mutations from 7-8 months to about 17 months, significantly delaying chemotherapy. This approach improves survival rates and helps patients maintain their professional and family lives.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What are the benefits of precision medicine for hormone receptor-positive breast cancer patients?
- A: Precision medicine can extend the stable period for hormone receptor-positive breast cancer patients and delay the need for chemotherapy, helping to maintain a better quality of life and daily functions.
- Q: How long can precision medication extend the stable period for hormone receptor-positive breast cancer patients with PIK3CA mutations?
- A: For patients with PIK3CA mutations, precision medication can extend the stable period from less than 1 year to approximately 17 months.